# Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)

> **NCT07660094** · PHASE3 · RECRUITING · sponsor: **Candel Therapeutics, Inc.** · enrollment: 500 (estimated)

## Conditions studied

- Non-squamous, Non-Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Aglatimagene Besadenovec
- **DRUG:** Valacyclovir
- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT07660094
- **Lead sponsor:** Candel Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-15
- **Primary completion:** 2031-10-22
- **Final completion:** 2031-10-22
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07660094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07660094, "Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07660094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*